Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Aug 6;21(16):5646.
doi: 10.3390/ijms21165646.

Proteotoxicity and Neurodegenerative Diseases

Clara Ruz  1 , Jose Luis Alcantud  1 , Francisco Vives Montero  1 , Raquel Duran  1 , Sara Bandres-Ciga  2
Affiliations
Review

Proteotoxicity and Neurodegenerative Diseases

Clara Ruz et al. Int J Mol Sci. .

Abstract

Neurodegenerative diseases are a major burden for our society, affecting millions of people worldwide. A main goal of past and current research is to enhance our understanding of the mechanisms underlying proteotoxicity, a common theme among these incurable and debilitating conditions. Cell proteome alteration is considered to be one of the main driving forces that triggers neurodegeneration, and unraveling the biological complexity behind the affected molecular pathways constitutes a daunting challenge. This review summarizes the current state on key processes that lead to cellular proteotoxicity in Alzheimer's disease, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis, providing a comprehensive landscape of recent literature. A foundational understanding of how proteotoxicity affects disease etiology and progression may provide essential insight towards potential targets amenable of therapeutic intervention.

Keywords: Alzheimer’s disease; Amyotrophic Lateral Sclerosis; Huntington disease; Parkinson’s disease; proteotoxicity.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Hou Y., Dan X., Babbar M., Wei Y., Hasselbalch S.G., Croteau D.L., Bohr V.A. Ageing as a risk factor for neurodegenerative disease. Nat. Rev. Neurol. 2019;15:565–581. doi: 10.1038/s41582-019-0244-7. - DOI - PubMed
    1. Sweeney P., Park H., Baumann M., Dunlop J., Frydman J., Kopito R., McCampbell A., Leblanc G., Venkateswaran A., Nurmi A., et al. Protein misfolding in neurodegenerative diseases: Implications and strategies. Transl. Neurodegener. 2017;6:6. doi: 10.1186/s40035-017-0077-5. - DOI - PMC - PubMed
    1. Kumar V., Sami N., Kashav T., Islam A., Ahmad F., Hassan M.I. Protein aggregation and neurodegenerative diseases: From theory to therapy. Eur. J. Med. Chem. 2016;124:1105–1120. doi: 10.1016/j.ejmech.2016.07.054. - DOI - PubMed
    1. Sameni S., Malacrida L., Tan Z., Digman M.A. Alteration in Fluidity of Cell Plasma Membrane in Huntington Disease Revealed by Spectral Phasor Analysis. Sci. Rep. 2018;8:734. doi: 10.1038/s41598-018-19160-0. - DOI - PMC - PubMed
    1. Bae B.-I., Xu H., Igarashi S., Fujimuro M., Agrawal N., Taya Y., Hayward S.D., Moran T.H., Montell C., Ross C.A., et al. p53 mediates cellular dysfunction and behavioral abnormalities in Huntington’s disease. Neuron. 2005;47:29–41. doi: 10.1016/j.neuron.2005.06.005. - DOI - PubMed